AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

⚠ Self-Insured Against Its Own ProductsModerate threat

Abbott Laboratories (ABT) — threat to the moat

Abbott self-insures its product liability, and in 2026 a sensor recall, a $385 million formula settlement and $670 million of NEC settlements arrived together.

Abbott does not buy insurance against its products hurting people. Its filings say "Product liability losses are self-insured" and could have a material adverse effect on its profitability1.

Abbott product-related settlements announced in 2026 ($M)670NEC settlements, Aug 2026385DOJ formula settlement, Sep 2026Abbott NEC release, 20 August 2026; US DOJ release, September 2026
More than a billion dollars in two months.

That choice is usually sensible for a company this size. It becomes a risk when several product problems arrive together, and in 2026 they did: a Class I recall of Libre 3 sensors with 860 serious injuries and seven deaths reported2, a $384,999,040 federal settlement over infant formula3 and an agreement to pay about $670 million to resolve NEC claims4.

Abbott's balance sheet can carry these. Operating cash flow was $9,566 million in 20255. But a self-insured company records each loss as it happens, and at 30 June 2026 Abbott had recorded no reserves for the NEC claims6.

The other legal reserves are modest. At 30 June 2026 Abbott estimated the range of possible loss for its various legal proceedings and environmental exposures at about $120 million to $530 million, with about $510 million accrued7.

The charges were already rising before 2026. Abbott's 2025 results included $165 million for legal reserves related to a negotiated settlement8, and the second quarter of 2026 a further $385 million legal reserve9.

The danger is in the total. Product-related legal charges above $1 billion in a single year, beyond those already announced, would show that self-insurance has become a cost of doing business rather than a saving.

References
  1. ReportedIts filings say "Product liability losses are self-insured" and could have a material adverse effect on its profitability.
    Abbott Laboratories Form 10-K for 2022 - the February 2022 Sturgis infant formula recall, the 16 May 2022 consent decree, recalled-brand US sales of $479 million against $1.2 billion, $176 million of recall charges, COVID-19 testing sales of $3.9bn, $7.7bn and $8.4bn in 2020-2022, net earnings and EPS for 2020-2022, and the statement that product liability losses are self-insured. — FY2022 · publ. February 2023 · source ↗
  2. ReportedIt becomes a risk when several product problems arrive together, and in 2026 they did: a Class I recall of Libre 3 sensors with 860 serious injuries and seven deaths reported, a $384,999,040 federal settlement over infant formula and an agreement to pay about $670 million to resolve NEC claims.
    AHA News, 4 February 2026 - FDA identifies a Class I recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors for glucose readings lower than actual; Abbott reported 860 serious injuries and seven deaths. — February 2026 · publ. 4 February 2026 · source ↗
  3. ReportedIt becomes a risk when several product problems arrive together, and in 2026 they did: a Class I recall of Libre 3 sensors with 860 serious injuries and seven deaths reported, a $384,999,040 federal settlement over infant formula and an agreement to pay about $670 million to resolve NEC claims.
    US Department of Justice release, September 2026 - Abbott agrees to pay $384,999,040 to resolve False Claims Act allegations over powder infant formula made at Sturgis, Michigan and Casa Grande, Arizona between 1 January 2018 and 31 December 2022; complaint in intervention filed 13 November 2025. — September 2026 · publ. September 2026 · source ↗
  4. ReportedIt becomes a risk when several product problems arrive together, and in 2026 they did: a Class I recall of Libre 3 sensors with 860 serious injuries and seven deaths reported, a $384,999,040 federal settlement over infant formula and an agreement to pay about $670 million to resolve NEC claims.
    Abbott Laboratories release of 20 August 2026, Form 8-K exhibit 99.1 - agreements to resolve the Gill case and NEC claims on behalf of about 2,000 other infants for about $670 million; the $495 million Gill verdict; three federal MDL bellwether wins; about 1,700 lawsuits remaining on behalf of about 12,700 infants. — August 2026 · publ. 20 August 2026 · source ↗
  5. ReportedOperating cash flow was $9,566 million in 2025.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - consolidated financial statements: income, taxes, cash flow, dividends, repurchases, debt, goodwill and the critical accounting policy on rebates. — FY2025 · publ. 20 February 2026 · source ↗
  6. ReportedBut a self-insured company records each loss as it happens, and at 30 June 2026 Abbott had recorded no reserves for the NEC claims.
    Abbott Laboratories Form 10-Q for the quarter ended 30 June 2026 - segment sales and operating earnings, the Exact Sciences acquisition and purchase-price allocation, the $20.0 billion of notes, remaining performance obligations, goodwill by segment, expected amortization, legal reserves and the NEC litigation, and the balance sheet at 30 June 2026 - legal proceedings: NEC litigation, reserves and the range of possible loss. — Q2 2026 · publ. 28 July 2026 · source ↗
  7. ReportedAt 30 June 2026 Abbott estimated the range of possible loss for its various legal proceedings and environmental exposures at about $120 million to $530 million, with about $510 million accrued.
    Abbott Laboratories Form 10-Q for the quarter ended 30 June 2026 - segment sales and operating earnings, the Exact Sciences acquisition and purchase-price allocation, the $20.0 billion of notes, remaining performance obligations, goodwill by segment, expected amortization, legal reserves and the NEC litigation, and the balance sheet at 30 June 2026 - legal proceedings: NEC litigation, reserves and the range of possible loss. — Q2 2026 · publ. 28 July 2026 · source ↗
  8. ReportedAbbott's 2025 results included $165 million for legal reserves related to a negotiated settlement, and the second quarter of 2026 a further $385 million legal reserve.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1 business and the segment note: the four segments, sales and operating earnings, employees, manufacturing sites, customers and geography. — FY2025 · publ. 20 February 2026 · source ↗
  9. ReportedAbbott's 2025 results included $165 million for legal reserves related to a negotiated settlement, and the second quarter of 2026 a further $385 million legal reserve.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - total sales, income statement, specified items, tax rate, guidance and the dividend. — Q2 2026 · publ. 16 July 2026 · source ↗
Sources
Generated October 6, 2026